Acne is one of the most common skin disorders clearly impacting people’s self-confidence and daily life. Therefore, La Roche-Posay focuses on finding innovative solutions to manage acne-prone skin¹.

A recent clinical study conducted by La Roche-Posay evaluated the efficacy of EFFACLAR DUO (+) on multiple clinical signs. For instance, EFFACLAR DUO (+) significantly reduces the severity of acne-prone skin in 25% of subjects after just one month.

Subjects included in the study where both female and male and where categorized phototype I to VI. The subjects applied EFFACLAR DUO (+) and EFFACLAR GEL MOUSSANT twice daily for 56 days.

EFFACLAR DUO (+) proved its efficacy by reducing imperfections in a timeframe starting from 28 days. With this efficacy, the severity of the imperfections improved, and results are visible. As an example, the visible improvement of phototype I and IV are shown²:

Acne is a burden to the daily life of patients especially when it reoccurs after treatment, an observational study found that acne relapses are associated to feelings of anger and fatality. The study shows how relapses can induce absenteeism and productivity loss³.

In this regard, La Roche-Posay conducted a second clinical study to evaluate the effect of EFFACLAR DUO (+) on relapses. Subjects were divided into 2 groups:

The differences in results between these 2 groups were evaluated.

Results show a superiority of EFFACLAR DUO (+) compared to the placebo. It improves some aspects of quality of life, and it has a better anti-relapse action. Concerning the last mentioned, EFFACLAR DUO (+) is a good therapeutic relay of BPO and allows to delay relapses up to 3 months after the end of BPO treatment⁴.

1. Shows visible efficacy
2. Decreases the impact on QOL
3. Proves to have a 3-month anti-relapse action
4. Works synergistically with BPO treatment.

¹Vilar GN, Santos LA, Sobral Filho JF. Quality of life, self-esteem and psychosocial factors in adolescents with acne vulgaris. An Bras Dermatol. 2015

²Clinical study, 87 men and women, EFFACLAR DUO+ + EFFACLAR GEL MOUSSANT, 56 days

³Dreno B, Bordet C, Seite S, Taieb C; ‘Registre Acné’ Dermatologists. Acne relapses: impact on quality of life and productivity. J Eur Acad Dermatol Venereol. 2019;33(5):937-943. doi:10.1111/jdv.15419

⁴Clinical study: Evaluation of the efficacy and tolerance of Effaclar DUO versus Placebo in acneic patients in association and in relay of 5% benzoyl peroxide during 6 months.